Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria

Winkler, Dietmar; Pjrek, Edda; Moser, Ulrike; Kasper, Siegfried

doi:10.1002/hup.839

Cited by 9 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of patients on medical leave due to depressive illness decreased steadily over the course of the trial, indicating a resumption of normal daily activities. These results are consistent with those of Winkler et al35 who reported a significant reduction in days of sick leave after 3 months of treatment with escitalopram (compared to days of sick leave during the 3 months before treatment).…”

Section: Discussionsupporting

confidence: 92%

Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial

Chokka

Legault²

2008

Depress. Anxiety

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial

Chokka

Legault²

2008

Depress. Anxiety

View full text Add to dashboard Cite

show abstract

“…The SASS is a widely used self-rating scale for the assessment of antidepressant treatment effects on social motivation and behavior [2] . The dosage of escitalopram at the end of our study (15.3 mg / day) was slightly higher than in previously published open studies in patients with different psychiatric diagnoses, in which mean doses of 11.6 mg / day [36] and 12.4 mg / day [44] were reported. Here, 9 patients were treated with 10 mg / day, 1 patient received 15 mg / day and 10 patients were on a daily dose of 20 mg.…”

Section: Discussioncontrasting

confidence: 74%

Escitalopram in Seasonal Affective Disorder: Results of an Open Trial

Pjrek

Winkler²,

Stastny³

et al. 2007

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…AD therapeutic approach was the predictor with the highest magnitude of association. Previous studies have attempted to estimate the effect of AD treatments on sick leave, however, they mainly focussed on AD classes or molecules (Winkler et al 2007;Gasse et al 2013;Wang et al 2015), rather than AD treatment approach. A systematic review by Lee confirmed that AD treatment improves workplace outcomes, including reductions in sick leave among adult patients with MDD (Lee et al 2018).…”

Section: Discussionmentioning

confidence: 99%

Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany

Kasper

Bonelli

Cattaneo

et al. 2021

International Journal of Psychiatry in Clinical Practice

Self Cite

View full text Add to dashboard Cite

Objective: To identify sick leave days (SLD) predictors after starting antidepressant (AD) treatment in patients affected by major depressive disorder (MDD), managed by general practitioners, with a focus on different AD therapeutic approaches. Methods: Retrospective study on German IQVIA V R Disease Analyser database. 19-64 year old MDD patients initiating AD treatment between July-2016 and June-2018 were grouped by therapeutic approach (AD monotherapy versus combination/switch/add-on). Data were analysed descriptively by AD therapeutic approach, while a zero-inflated Poisson (ZIP) multiple regression model was run to evaluate SLD predictors. Results: 8,891 patients met inclusion criteria (monotherapy: 66%; combination/switch/add-on: 34%). All covariates had an influence on SLD after AD treatment initiation. Focussing on variables that physicians may more easily intervene to improve outcomes, it was found that the expected SLD number of combination/switch/add-on patients was 1.6 times that of monotherapy patients, and the expected SLD number of patients diagnosed with MDD before the decision to start AD treatment was 1.2 times that of patients not diagnosed with MDD. Conclusions: A patient tailored approach in the selection of AD treatment at the time of MDD diagnosis may improve functional recovery and help to reduce the socio-economic burden of the disease. KEY POINTSFew studies previously investigated the effect of antidepressant treatment approaches on sick leave days in major depressive disorder. To the authors' knowledge, this is the first study evaluating the effect of different antidepressant treatment approaches on sick leave days in major depressive disorder in German patients. Patients receiving antidepressant monotherapy treatment seemed to lose fewer working days than patients receiving antidepressants combination/switch/add-on therapy, both before and after starting treatment, even if differences were more pronounced after treatment has started. The use of antidepressant monotherapy or combination/switch/add-on therapy was the strongest predictor of sick leave days after starting antidepressant treatment: the expected number of sick leave days for the combination/switch/add-on group was 1.6 times that of the monotherapy group. Among factors associated with increased sick leave days, antidepressant therapeutic approach and the promptness of starting the antidepressant treatment when major depressive disorder is diagnosed, are those on which physicians may more easily intervene to improve outcomes. Findings from the present study suggest that a patient tailored approach may improve functional recovery and help reducing the socio-economic burden of the disease.

show abstract

Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria

Abstract: Our results suggest that escitalopram is an efficacious and overall well-tolerated treatment in a naturalistic sample of working patients. A decrease in the days on sick leave is indicative of indirect cost-effectiveness of this treatment.

Cited by 9 publications

References 31 publications

Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial

Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial

Escitalopram in Seasonal Affective Disorder: Results of an Open Trial

Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany

Contact Info

Product

Resources

About